ScholarLens Back to search
2021•Journal of Cystic FibrosisOpen access

609: Elexacaftor as a CFTR potentiator: Synergism with ivacaftor and implications for new combination drug therapies for cystic fibrosis

Ciarán A. Shaughnessy, Pamela L. Zeitlin, Preston E. Bratcher

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ivacaftor, Potentiator, Cystic fibrosis, Medicine, Drug, Cystic fibrosis transmembrane conductance regulator, Pharmacology, Internal medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
609: Elexacaftor as a CFTR potentiator: Synergism with ivacaftor and implications for new combination drug therapies for cystic fibrosis — Research Paper | ScholarLens